Skip to main content
Top

11-06-2015 | Gastric cancer | Book chapter | Article

17. Managing Early and Late Postoperative Complications Following Gastric Surgery

Authors: Brian Badgwell, MD, MS, Ryan Day, MD, Assoc. Prof. Thomas Aloia, MD

Publisher: Springer International Publishing

Abstract

Gastric cancer surgery is associated with morbidity rates of 20–30 % and 30-day mortality rates of 4–5 %, based on multi-institutional quality improvement program data. Patients who undergo total gastrectomy have higher morbidity and mortality rates than do patients who undergo subtotal gastrectomy. Resection of adjacent organs also increases the risk of major postoperative complications. Frequently reported complications after gastrectomy include wound and intra-abdominal infection, dehiscence, pulmonary complications, myocardial infarction, thromboembolic complications, and anastomotic leakage. In addition to the standard early postoperative complications of major abdominal surgery, patients undergoing gastric resection are prone to several unique clinical syndromes often referred to as postgastrectomy syndromes. Although these syndromes were more common when peptic ulcer disease was frequently treated with surgery, these syndromes may also manifest in long-term survivors of gastric cancer and therefore are important survivorship issues. Postgastrectomy syndromes and late complications discussed in this chapter include dumping syndrome, afferent limb syndrome, efferent limb syndrome, Roux stasis syndrome, bile reflux gastritis, and postvagotomy diarrhea.
Literature
1.
Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340(12):908–14.PubMedCrossRef
2.
Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347(9007):995–9.PubMedCrossRef
3.
Degiuli M, Sasako M, Ponti A, et al. Morbidity and mortality after D2 gastrectomy for gastric cancer: results of the Italian Gastric Cancer Study Group prospective multicenter surgical study. J Clin Oncol. 1998;16(4):1490–3.PubMed
4.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.PubMedCrossRef
5.
Wang Z, Chen J, Su K, et al. Abdominal drainage versus no drainage post gastrectomy for gastric cancer. Cochrane Database Syst Rev. 2011;10(8):CD008788.
6.
Papenfuss WA, Kukar M, Oxenberg J, et al. Morbidity and mortality associated with gastrectomy for gastric cancer. Ann Surg Oncol. 2014;21:3008–14.PubMedCrossRef
7.
Grossmann EM, Longo WE, Virgo KS, et al. Morbidity and mortality of gastrectomy for cancer in Department of Veterans Affairs Medical Centers. Surgery. 2002;131(5):484–90.PubMedCrossRef
8.
Kubo M, Sasako M, Gotoda T, et al. Endoscopic evaluation of the remnant stomach after gastrectomy: proposal for a new classification. Gastric Cancer. 2002;5(2):83–9.PubMedCrossRef
9.
Lang H, Piso P, Stukenborg C, et al. Management and results of proximal anastomotic leaks in a series of 1114 total gastrectomies for gastric carcinoma. Eur J Surg Oncol. 2000;26(2):168–71.PubMedCrossRef
10.
Sierzega M, Kolodziejczyk P, Kulig J. Impact of anastomotic leakage on long-term survival after total gastrectomy for carcinoma of the stomach. Br J Surg. 2010;97(7):1035–42.PubMedCrossRef
11.
Tokunaga M, Tanizawa Y, Bando E, et al. Poor survival rate in patients with postoperative intraabdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol. 2013;20(5):1575–83.PubMedCrossRef
12.
Alldinger I, Schmitt MM, Dreesbach J, et al. Endoscopic treatment of anastomotic leakage after esophagectomy or gastrectomy for carcinoma with self-expanding removable stents. Hepatogastroenterology. 2014;61(129):111–4.PubMed
13.
Blackmon SH, Santora R, Schwarz P, et al. Utility of removable esophageal covered self-expanding metal stents for leak and fistula management. Ann Thorac Surg. 2010;89(3):931–6 (discussion 936–7).PubMedCrossRef
14.
Yoo HM, Lee HH, Shim JH, et al. Negative impact of leakage on survival of patients undergoing curative resection for advanced gastric cancer. J Surg Oncol. 2011;104(7):734–40.PubMedCrossRef
15.
McCulloch P, Ward J, Tekkis PP. Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study. BMJ. 2003;327(7425):1192–7.PubMedCentralPubMedCrossRef
16.
Ukleja A. Dumping syndrome: pathophysiology and treatment. Nutr Clin Pract. 2005;20(5):517–25.PubMedCrossRef
17.
Mine S, Sano T, Tsutsumi K, et al. Large-scale investigation into dumping syndrome after gastrectomy for gastric cancer. J Am Coll Surg. 2010;211(5):628–36.PubMedCrossRef
18.
van der Kleij FG, Vecht J, Lamers CB, et al. Diagnostic value of dumping provocation in patients after gastric surgery. Scand J Gastroenterol. 1996;31(12):1162–6.PubMedCrossRef
19.
Li-Ling J, Irving M. Therapeutic value of octreotide for patients with severe dumping syndrome—a review of randomised controlled trials. Postgrad Med J. 2001;77(909):441–2.PubMedCentralPubMedCrossRef
20.
Arts J, Caenepeel P, Bisschops R, et al. Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping. Clin Gastroenterol Hepatol. 2009;7(4):432–7.PubMedCrossRef
21.
Didden P, Penning C, Masclee AA. Octreotide therapy in dumping syndrome: analysis of long-term results. Aliment Pharmacol Ther. 2006;24(9):1367–75.PubMedCrossRef
22.
Vecht J, Lamers CB, Masclee AA. Long-term results of octreotide-therapy in severe dumping syndrome. Clin Endocrinol (Oxf). 1999;51(5):619–24.CrossRef
23.
Sawyers JL, Herrington JL Jr. Superiority of antiperistaltic jejunal segments in management of severe dumping syndrome. Ann Surg. 1973;178(3):311–21.PubMedCentralPubMedCrossRef
24.
Eagon JC, Miedema BW, Kelly KA. Postgastrectomy syndromes. Surg Clin North Am. 1992;72(2):445–65.PubMed
25.
Miedema BW, Kelly KA, Camilleri M, et al. Human gastric and jejunal transit and motility after Roux gastrojejunostomy. Gastroenterology. 1992;103(4):1133–43.PubMed
26.
Osugi H, Fukuhara K, Takada N, et al. Reconstructive procedure after distal gastrectomy to prevent remnant gastritis. Hepatogastroenterology. 2004;51(58):1215–8.PubMed
27.
Csendes A, Burgos AM, Smok G, et al. Latest results (12–21 years) of a prospective randomized study comparing Billroth II and Roux-en-Y anastomosis after a partial gastrectomy plus vagotomy in patients with duodenal ulcers. Ann Surg. 2009;249(2):189–94.PubMedCrossRef
28.
Nicolai JJ, Speelman P, Tytgat GN, et al. Comparison of the combination of cholestyramine/alginates with placebo in the treatment of postgastrectomy biliary reflux gastritis. Eur J Clin Pharmacol. 1981;21(3):189–94.PubMedCrossRef
29.
Buch KL, Weinstein WM, Hill TA, et al. Sucralfate therapy in patients with symptoms of alkaline reflux gastritis. A randomized, double-blind study. Am J Med. 1985;79(2C):49–54.PubMedCrossRef
30.
Stefaniwsky AB, Tint GS, Speck J, et al. Ursodeoxycholic acid treatment of bile reflux gastritis. Gastroenterology. 1985;89(5):1000–4.PubMed
31.
Davidson ED, Hersh T. The surgical treatment of bile reflux gastritis: a study of 59 patients. Ann Surg. 1980;192(2):175–8.PubMedCentralPubMedCrossRef
32.
Capussotti L, Marucci MM, Arico S, et al. Longterm results of surgical treatment for alkaline reflux gastritis in gastrectomized patients. Am J Gastroenterol. 1984;79(12):924–6.PubMed
33.
Tasse D, Ghosn PO, Gagnon M, et al. Alkaline reflux gastritis: Roux-en-Y diversion is effective. Can J Surg. 1982;25(3):337–9.PubMed
34.
Bondurant FJ, Maull KI, Nelson HS Jr, et al. Bile reflux gastritis. South Med J. 1987;80(2):161–5.PubMedCrossRef